<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379391</url>
  </required_header>
  <id_info>
    <org_study_id>TPO-HSCT-2011</org_study_id>
    <nct_id>NCT01379391</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT</brief_title>
  <acronym>TPO</acronym>
  <official_title>A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong No.2 Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Overseas Chinese Hospital,Guangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Factors influencing platelet engraftment after allogeneic hematopoietic stem cell
      transplantation (Allo-HSCT) includes previous chemotherapy courses, conditioning regimen, HLA
      compatibility, source of stem cell, CD34+ cell count, infection of virus/bacteria/fungal,
      graft-versus-host disease (GVHD), etc. Large-scaled clinical trials have demonstrated that
      platelet count below 20G/L on 14 days after transplantation is an predictive factor for
      delayed platelet engraftment, which lead to increased platelet infusion requirement and high
      risk of bleeding. Multivariable survival analysis indicated that delayed platelet engraftment
      in Allo-HSCT is independent predictive factor for transplantation related mortality (TRM).
      But effective treatment approaches for delayed platelet recovery after Allo-HSCT are still
      lacking now.

      Recombinant human thrombopoietin (rHuTPO) is a fully modified recombinant human
      thrombopoietin accurately expressed in mammalian cells. The rHuTPO agent manufactured by the
      3Bio Pharmaceutical Limited Liability Company (LLC) in Shenyang is approved by the State Food
      and Drug Administration (SFDA) of China in 2005 and is the first rHuTPO agent available
      globally. RHuTPO was approved for for immune thrombocytopenia and chemotherapy-related
      thrombocytopenia in China. Animal experiments showed that TPO-mobilizing stem cell could
      promote platelet engraftment in Allo-HSCT in mice. As for efficacy and safety of TPO on
      platelet engraftment after Allo-HSCT, it's marginally addressed in clinical trials.

      Based on preliminary research results, investigator designed a phase IV, open-label,
      prospective, multicenter Study of the efficacy and safety of recombinant human thrombopoietin
      injection (rHuTPO, TPIAO)on platelet engraftment in Allo-HSCT in China.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Response Rate to TPO</measure>
    <time_frame>4 weeks</time_frame>
    <description>Response Rate is selected as primary outcome for measuring efficacy of TPO for patients with delayed platelet engraftment after Allo-HSCT.
Markedly response: Platelet count of more than 50G/L in complete blood count on +28d post-transplantation after finishing 14-day course of TPO intervention, or PLTâ‰¥100G/L within the 14-day course.
Response: PLT 20-50G/L on +28 day after completing the 14-day course. No response: PLT &lt;20G/L on +28 day after completing the 14-day course.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplantation Related Mortality (TRM)</measure>
    <time_frame>1 year</time_frame>
    <description>Transplantation related mortality (TRM) in two arms after Allo-HSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Myeloablative</condition>
  <condition>Delayed Platelet Engraftment</condition>
  <arm_group>
    <arm_group_label>TPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPO-Free Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No TPO intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Thrombopoietin (rHTPO)</intervention_name>
    <description>Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.
Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT.</description>
    <arm_group_label>TPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages: 18 years to 65 years.

          2. Patients received myeloablative allogeneic hematopoietic stem cell transplantation
             from related or non-related, HLA compatible or incompatible donors. History controls
             or concurrent controls are used.

          3. The platelet count is lower than 20G/L on +14d post-transplant .

          4. The informed consent form has been signed.

          5. The following exclusion criteria are excluded.

        Exclusion Criteria:

          1. Patients received non-myeloablative hematopoietic stem cell transplantation.

          2. Patients with severe cardio-cerebral diseases with over grade III A YHA cardiac
             function or with past history of coronary heart disease, cerebral thrombosis, cerebral
             arteriosclerosis, etc.

          3. Patients with severe hepatic or renal dysfunction with more than 5 times the upper
             limit of normal range (ULN) of serum ALT or AST levels, or with more than 5 times the
             upper limit of normal range (ULN) of serum TBIL level or less than 40% of normal
             prothrombin time activity (PTA); or with more than 3 times the ULN of serum Cr.

          4. Patients with history of deep vein thrombosis within 8 weeks of enrollment.

          5. Patients with hepatic obstructive venous disease without recovery within 2 weeks of
             enrollment.

          6. Patients with thrombotic microangiopathy without recovery within 2 weeks of
             enrollment.

          7. Patients with capillary leaking syndrome without recovery within 2 weeks of
             enrollment.

          8. Patients with other conditions considered unsuitable for the study.

          9. Patients with hypercoagulopathy condition with two or more of these criteria: INR
             lower than 0.82, APTT lower than the lower limit of normal values (23 seconds) or PT
             lower than the lower limit of normal values (10 seconds).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Nanfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongsheng Zhou, PhD MD</last_name>
    <phone>86-20-62787883</phone>
    <email>hanson2008@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Command</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Xiao, MD</last_name>
      <email>jdxiao111@163.com</email>
    </contact>
    <investigator>
      <last_name>Yang Xiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suijin Wu, MD</last_name>
      <email>songwu55555@163.com</email>
    </contact>
    <investigator>
      <last_name>Suijin Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duorong Xu, MD</last_name>
      <email>xudr@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Duorong Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Li, MD PhD</last_name>
      <email>li_yuhua@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yuhua Li, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong No.2 Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510317</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhang, MD</last_name>
      <email>zhqing@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Qing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Zhou, MD PhD</last_name>
      <phone>86-20-62787883</phone>
      <email>hanson2008@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hongsheng Zhou, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qifa Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guopan Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xian Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mo Yang, PhD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanyi Meng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Overseas Chinese Hospital,Guangdong</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanger Zhu, MD</last_name>
      <email>tzhuker@jnu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Kanger Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongjun Lin, MD</last_name>
      <email>lindongjun0168@163.com</email>
    </contact>
    <investigator>
      <last_name>Dongjun Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan People Hospital,Guangdong</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Xu, MD</last_name>
      <email>doctorxu@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaojun Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nfyy.com</url>
    <description>Website of Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Platelet Engraftment</keyword>
  <keyword>TPO</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

